Sidekick Health raises Series B growth funding of USD 55 Million
Category: #health  By Pankaj Singh  Date: 2022-05-06
 | 
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Sidekick Health raises Series B growth funding of USD 55 Million

Sidekick Health, an Iceland-based digital healthcare business, has reportedly raised a Series B growth funding of USD 55 million.

The latest round is initiated by Novator Ventures, a London-based VC firm, with participation from Frumtak Ventures, Asabys Partners, and Wellington Partners as well as a U.S.-based strategic investor. Sidekick previously raised a Series A round of USD 20 million two years ago.

With the closure of the Series B round, Novator Ventures’ Founder and General Partner Birgir Mar Ragnarsson will join Sidekick’s board.

Mr. Ragnarsson revealed that Sidekick will now be recognized as a global player in digital therapeutics. He added that the VC firm identifies the significant avenues presented by third-generation therapeutics as well as Sidekick’s ability to upscale and operate at a global level.

Although Sidekick Health is not registering significant customer numbers, it has signed alliances with some of the major healthcare players like Anthem to provide digital care programs along with pharma giants Pfizer and Bayer to develop an integrated combination therapeutics comprising a digital and molecular drug therapeutic.

According to the startup, it assisted more than 40,000 patients worldwide, with its products available in six languages. The U.S. and Europe are its major markets, with offices in Germany, the U.S., Sweden, and Iceland.

Although the U.S. and Europe are currently its largest markets, Sidekick is establishing some partnerships in Asia. But these are early days, and the company will be mainly focusing on increasing its commercial presence in the United States.

Major pharma companies are interested in digital therapeutics not only as a tool to possibly augment their drug efficacy but also as a method to extend medicinal value.

This allows major players to file for new patents connecting current medicines to digital therapeutic programs that are way more affordable and easier to develop than the expensive business of drug research and discovery.

Source credit:

https://techcrunch.com/2022/05/04/sidekick-health-series-b/



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

Rona Therapeutics obtains global rights to Sanofi's siRNA platform

Rona Therapeutics obtains global rights to Sanofi's siRNA platform

By Pankaj Singh

Rona Therapeutics Inc has reportedly acquired the global exclusive rights to the siRNA platform of delivery moiety and chemical modification from Sanofi S.A., in addition to four pre-clinical contenders for unrevealed ...

Toy maker Mattel inks multi-year agreement with Elon Musk’s SpaceX

Toy maker Mattel inks multi-year agreement with Elon Musk’s SpaceX

By Pankaj Singh

California-based toy manufacturing and entertainment company, Mattel, has recently signed a multi-year agreement with Elon Musk’s private spaceflight company, SpaceX.

T...

USHV partners with Willowbrook to provide quality cardiovascular care

USHV partners with Willowbrook to provide quality cardiovascular care

By Pankaj Singh

US Heart & Vascular (USHV) is reportedly partnering with Willowbrook Cardiovascular Associates to offer quality cardiovascular care in the Houston market.

USHV has a strong ma...